These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 31914038)

  • 1. Survival analysis of patients with glioblastoma treated by long-term administration of temozolomide.
    Quan R; Zhang H; Li Z; Li X
    Medicine (Baltimore); 2020 Jan; 99(2):e18591. PubMed ID: 31914038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
    Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
    Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged Temozolomide Maintenance Therapy in Newly Diagnosed Glioblastoma.
    Skardelly M; Dangel E; Gohde J; Noell S; Behling F; Lepski G; Borchers C; Koch M; Schittenhelm J; Bisdas S; Naumann A; Paulsen F; Zips D; von Hehn U; Ritz R; Tatagiba MS; Tabatabai G
    Oncologist; 2017 May; 22(5):570-575. PubMed ID: 28360216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiochemotherapy with temozolomide for patients with glioblastoma. Prognostic factors and long-term outcome of unselected patients from a single institution.
    Gerstein J; Franz K; Steinbach JP; Seifert V; Rödel C; Weiss C
    Strahlenther Onkol; 2011 Nov; 187(11):722-8. PubMed ID: 22037649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Super-early initiation of temozolomide prolongs the survival of glioblastoma patients without gross-total resection: a retrospective cohort study.
    Jiang H; Zeng W; Ren X; Cui Y; Li M; Yang K; Elbaroody M; Lin S
    J Neurooncol; 2019 Aug; 144(1):127-135. PubMed ID: 31175579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temozolomide in glioblastoma treatment: 15-year clinical experience and analysis of its efficacy.
    Glavatskyi OY; Zemskova OV; Khmelnytskyi HV; Kardash KA; Shuba IM; Stuley VA
    Exp Oncol; 2020 Jun; 42(2):148-156. PubMed ID: 32602292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone marrow response as a potential biomarker of outcomes in glioblastoma patients.
    Vaios EJ; Nahed BV; Muzikansky A; Fathi AT; Dietrich J
    J Neurosurg; 2017 Jul; 127(1):132-138. PubMed ID: 27739940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of long-term adjuvant temozolomide chemotherapy on primary glioblastoma patient survival.
    Huang B; Yu Z; Liang R
    BMC Neurol; 2021 Nov; 21(1):424. PubMed ID: 34724914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.
    Kim BS; Seol HJ; Nam DH; Park CK; Kim IH; Kim TM; Kim JH; Cho YH; Yoon SM; Chang JH; Kang SG; Kim EH; Suh CO; Jung TY; Lee KH; Kim CY; Kim IA; Hong CK; Yoo H; Kim JH; Kang SH; Kang MK; Kim EY; Kim SH; Chung DS; Hwang SC; Song JH; Cho SJ; Lee SI; Lee YS; Ahn KJ; Kim SH; Lim DH; Gwak HS; Lee SH; Hong YK
    Cancer Res Treat; 2017 Jan; 49(1):193-203. PubMed ID: 27384161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.
    Gramatzki D; Kickingereder P; Hentschel B; Felsberg J; Herrlinger U; Schackert G; Tonn JC; Westphal M; Sabel M; Schlegel U; Wick W; Pietsch T; Reifenberger G; Loeffler M; Bendszus M; Weller M
    Neurology; 2017 Apr; 88(15):1422-1430. PubMed ID: 28298550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis.
    Wang J; Huang Y; Zhao F; Chen J; He L; Liu Z; Pei Y; Wei Z; Li R; Ai P; Peng X
    J Neurooncol; 2022 Nov; 160(2):433-443. PubMed ID: 36357822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the clinical efficacy of temozolomide (TMZ) versus nimustine (ACNU)-based chemotherapy in newly diagnosed glioblastoma.
    Wang Y; Chen X; Zhang Z; Li S; Chen B; Wu C; Wang L; Zhang X; Wang J; Chen L; Jiang T
    Neurosurg Rev; 2014 Jan; 37(1):73-8. PubMed ID: 23912878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective comparison of standard and escalated doses of radiotherapy in newly diagnosed glioblastoma patients treated with concurrent and adjuvant temozolomide.
    Guler OC; Yıldırım BA; Önal C; Topkan E
    Indian J Cancer; 2019; 56(1):59-64. PubMed ID: 30950447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme.
    Roldán Urgoiti GB; Singh AD; Easaw JC
    J Neurooncol; 2012 May; 108(1):173-7. PubMed ID: 22382781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience.
    Jeon HJ; Kong DS; Park KB; Lee JI; Park K; Kim JH; Kim ST; Lim DH; Kim WS; Nam DH
    Clin Neurol Neurosurg; 2009 Oct; 111(8):679-82. PubMed ID: 19640635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide.
    Hata N; Mizoguchi M; Kuga D; Hatae R; Akagi Y; Sangatsuda Y; Amemiya T; Michiwaki Y; Fujioka Y; Takigawa K; Suzuki SO; Yoshitake T; Togao O; Hiwatashi A; Yoshimoto K; Iihara K
    J Neurooncol; 2020 Feb; 146(3):451-458. PubMed ID: 32020475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.
    Krauze AV; Myrehaug SD; Chang MG; Holdford DJ; Smith S; Shih J; Tofilon PJ; Fine HA; Camphausen K
    Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):986-992. PubMed ID: 26194676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility and safety of extended adjuvant temozolomide beyond six cycles for patients with glioblastoma.
    Hsieh SY; Chan DT; Kam MK; Loong HH; Tsang WK; Poon DM; Ng SC; Poon WS
    Hong Kong Med J; 2017 Dec; 23(6):594-8. PubMed ID: 28798282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
    Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
    Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.